Skip to content

Efficacy and Cost Analysis of Steroids in Treatment of Otitis Media With Effusion

Efficacy and Cost Analysis of Steroids in Treatment of Otitis Media With Effusion (OME) Compared to That of Combination of Antibiotic, Antihistaminic, and Nasal Decongestant

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03590912
Enrollment
160
Registered
2018-07-18
Start date
2018-09-05
Completion date
2020-03-18
Last updated
2020-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Otitis Media With Effusion

Brief summary

We intend to study the cost of treatment, efficacy and adverse effects for Otitis media with effusion.

Detailed description

Treatment groups would be: 1. Cefpodoxime + oxymetaxoline drops + levocetirizine 2. Fluticasone intranasal spray 3. Short term oral steroids 4. Wait and watch

Interventions

DRUGMometasone 50 Mcg/Inh Nasal Spray

One spray in each nostril once daily for one month

DRUGAntibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%)

Children in this group will be treated with antiboitics (syp cefpodoxime) at 10 mg/kg/day in two divided dose for a week, plus antihistamine and nasal decongestants. Oral levocetirizine (Syrup levocet 2.5 mg/5ml) 1.25 mg once daily for age up to six years, 2.5 mg once daily for elder children for a month, plus oxymetazoline (Nasivion) 0.025%, 4 drops twice daily for two weeks

DRUGSteroid Drug (prednisolone)

This group will be treated with steroid drugs. Oral prednisolone, 1 mg/kg body weight daily in two divided dose for 1 week followed by half mg/kg/day in two divided dose for next one week.

Sponsors

Lumbini Medical College
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
1 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* history of mild ear ache or decreased hearing for three or more months, plus * intact and immobile tympanic membrane by pneumatic otoscopy * Type B tympanogram

Exclusion criteria

* any external ear condition that hampers visualization of tympanic membrane * lost to follow up

Design outcomes

Primary

MeasureTime frame
Non B type tympanogramone month

Secondary

MeasureTime frame
cost of treatmentone month
Adverse effectsone month

Countries

Nepal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026